Abstract
Numerous studies have shown that the presence of homologous recombination deficiency (HRD) in breast tumors may be a good marker of the effectiveness of chemotherapy with DNA-damaging agents such as platinum-based and anthracycline-containing medication regimens. However, the formation of HRD due to disruptions in the BRCA1/2 genes is typical not only for breast cancer and ovarian cancer, but also for other cancer localizations, in particular for non-small cell lung cancer (NSCLC). Since the use of platinum-based drugs in patients with NSCLC is a standard treatment protocol, studying the expression profile of homologous recombination genes and the presence of chromosomal aberrations therein will allow us to fully study HRD in these patients and identify new prognostic markers.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
